Alzecure Pharma – ESG risk research and ESG rating

We at sustainAX have ESG risk researched and ESG risk rated Alzecure Pharma and our clients can access the reseach on their Bloomberg terminals.

Alzecure Pharma is in the materiality based sector of PHARMA, BIOTECH AND LIFE SCIENCES.

About the company:

AlzeCure Pharma develops new drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain, for which currently available treatment is extremely limited. AlzeCure® aims to pursue its own projects through preclinical research and development to an early clinical phase. NeuroRestore® – the platform is developing a new generation of symptom-relieving drugs for the treatment of illnesses with cognitive disorders, such as Alzheimer’s disease. Alzstatin® – the platform develops innovative disease-modifying and preventive drugs for Alzheimer’s disease. Painless – two projects: TrkA-NAM and ACD440, which both focus on severe pain.

Are you interested in the ESG research and ESG rating?

If you are interested in the ESG risk research and ESG risk rating of Alzecure Pharma, contact us at sustainAX

Generated by MPG